Compare · ELTX vs NVO
ELTX vs NVO
Side-by-side comparison of Elicio Therapeutics Inc. (ELTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $219.94B, about 3184.7x ELTX ($69.1M).
- Over the past year, ELTX is down 71.1% and NVO is down 26.4% - NVO leads by 44.8 points.
- ELTX has been more active in the news (6 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 4 for ELTX).
- Company
- Elicio Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $2.93-2.33%
- $50.81+2.28%
- Market cap
- $69.1M
- $219.94B
- 1M return
- -26.47%
- +5.83%
- 1Y return
- -71.10%
- -26.35%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 5
- Recent ratings
- 4
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELTX
- SEC Form 4 filed by Officer Haqq Christopher
- SEC Form 4 filed by Chief Scientific Officer Demuth Peter
- SEC Form 4 filed by CEO, President and Director Connelly Robert
- SEC Form 4 filed by Officer Shah Preetam
- Amendment: SEC Form SCHEDULE 13G/A filed by Elicio Therapeutics Inc.
- Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
- SEC Form 424B5 filed by Elicio Therapeutics Inc.
- Elicio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
- Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S